132 related articles for article (PubMed ID: 1877394)
1. Enhanced expression of the cellular oncogene MYCN and progression of human neuroblastoma.
Schwab M
Adv Enzyme Regul; 1991; 31():329-38. PubMed ID: 1877394
[TBL] [Abstract][Full Text] [Related]
2. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
Schwab M
Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
[TBL] [Abstract][Full Text] [Related]
3. Oncogene amplification in neoplastic development and progression of human cancers.
Schwab M
Crit Rev Oncog; 1990; 2(1):35-51. PubMed ID: 2091749
[TBL] [Abstract][Full Text] [Related]
4. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration.
Schwab M
Verh Dtsch Ges Pathol; 1994; 78():26-33. PubMed ID: 7533996
[TBL] [Abstract][Full Text] [Related]
5. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
6. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma--clinical applications of molecular parameters.
Brodeur GM
Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
[TBL] [Abstract][Full Text] [Related]
8. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
9. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
10. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer.
Schwab M; Amler LC
Genes Chromosomes Cancer; 1990 Jan; 1(3):181-93. PubMed ID: 1982063
[TBL] [Abstract][Full Text] [Related]
11. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
12. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.
Schwab M
Naturwissenschaften; 1999 Feb; 86(2):71-8. PubMed ID: 10084150
[TBL] [Abstract][Full Text] [Related]
13. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
14. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
15. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells.
Corvi R; Savelyeva L; Schwab M
Cancer Res; 1995 Aug; 55(16):3471-4. PubMed ID: 7627947
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
[TBL] [Abstract][Full Text] [Related]
17. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.
Hogarty MD
Cancer Lett; 2003 Jul; 197(1-2):173-9. PubMed ID: 12880978
[TBL] [Abstract][Full Text] [Related]
18. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
19. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
[TBL] [Abstract][Full Text] [Related]
20. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
